Predictive Utility of a Coronary Artery Disease Polygenic Risk Score in Primary Prevention
Top Cited Papers
Open Access
- 1 February 2023
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Cardiology
- Vol. 8 (2) , 130-137
Abstract
Importance: The clinical utility of polygenic risk scores (PRS) for coronary artery disease (CAD) has not yet been established.Objective: To investigate the ability of a CAD PRS to potentially guide statin initiation in primary prevention after accounting for age and clinical risk.Design, Setting, and Participants: This was a longitudinal cohort study with enrollment starting on January 1, 2006, and ending on December 31, 2010, with data updated to mid-2021, using data from the UK Biobank, a long-term population study of UK citizens. A replication analysis was performed in Biobank Japan. The analysis included all patients without a history of CAD and who were not taking lipid-lowering therapy. Data were analyzed from January 1 to June 30, 2022.Exposures: Polygenic risk for CAD was defined as low (bottom 20%), intermediate, and high (top 20%) using a CAD PRS including 241 genome-wide significant single-nucleotide variations (SNVs). The pooled cohort equations were used to estimate 10-year atherosclerotic cardiovascular disease (ASCVD) risk and classify individuals as low (60 years: HR, 1.42; 95% CI, 1.37-1.48; P for interaction <.001). In patients younger than 50 years, those with high PRS had a 3- to 4-fold increased associated risk of MI compared with those in the low PRS category. A significant interaction between CAD PRS and age was replicated in Biobank Japan. When CAD PRS testing was added to the clinical ASCVD risk score in individuals younger than 50 years, 591 of 4373 patients (20%) with borderline risk were risk stratified into intermediate risk, warranting initiation of statin therapy and 3198 of 7477 patients (20%) with both borderline or intermediate risk were stratified as low risk, thus not warranting therapy.Conclusions and Relevance: Results of this cohort study suggest that the predictive ability of a CAD PRS was greater in younger individuals and can be used to better identify patients with borderline and intermediate clinical risk who should initiate statin therapy.Keywords
This publication has 22 references indexed in Scilit:
- Overview of the BioBank Japan Project: Study design and profileJournal of Epidemiology, 2017
- Cross-sectional analysis of BioBank Japan clinical data: A large cohort of 200,000 patients with 47 common diseasesJournal of Epidemiology, 2017
- Genetic Risk, Adherence to a Healthy Lifestyle, and Coronary DiseaseNew England Journal of Medicine, 2016
- The impact of communicating genetic risks of disease on risk-reducing health behaviour: systematic review with meta-analysisBMJ, 2016
- A comprehensive 1000 Genomes–based genome-wide association meta-analysis of coronary artery diseaseNature Genetics, 2015
- Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trialsThe Lancet, 2015
- Doubly robust estimation of attributable fractions in survival analysisStatistical Methods in Medical Research, 2014
- Comparing two correlated C indices with right‐censored survival outcome: a one‐shot nonparametric approachStatistics in Medicine, 2014
- 2013 ACC/AHA Guideline on the Assessment of Cardiovascular RiskCirculation, 2014
- Effect of Direct-to-Consumer Genomewide Profiling to Assess Disease RiskNew England Journal of Medicine, 2011